MasTec Inc

More

• Goldman Sachs must face fraud claims from insurer -N.Y. court Tuesday, 7 May 2013 | 2:35 PM ET

  NEW YORK, May 7- Goldman Sachs Group Inc must face fraud claims brought by CIFG Assurance North America. The New York State Supreme Court's Appellate Division, First Department, reversed on Tuesday, finding that CIFG had done enough by having an outside consultant analyze the loans.

• MARKET PULSE-LinkedIn, Arena Pharma, Radcom, Delcath, Solar stocks Friday, 3 May 2013 | 3:35 PM ET

  **RADCOM LTD, $4.05, up 53 pct. **DELCATH SYSTEMS INC, $0.43, down 45 pct. **LINKEDIN CORP, $181.69, down 10 pct.

• CORRECTED-MARKET PULSE-LinkedIn, Arena Pharma, Radcom, Delcath, YRC Worldwide Friday, 3 May 2013 | 2:02 PM ET

  **RADCOM LTD, $4.05, up 53 pct. **DELCATH SYSTEMS INC, $0.43, down 45 pct. **LINKEDIN CORP, $181.69, down 10 pct.

• MARKET PULSE-LinkedIn, Arena Pharma, Radcom, Delcath, YRC Worldwide Friday, 3 May 2013 | 1:29 PM ET

  **RADCOM LTD, $4.05, up 53 pct. **DELCATH SYSTEMS INC, $0.43, down 45 pct. **LINKEDIN CORP, $181.69, down 10 pct.

• MARKET PULSE-LinkedIn, Arena Pharma, Radcom, Chemed, Vocera, Procera Friday, 3 May 2013 | 11:27 AM ET

  **LINKEDIN CORP, $186.46, down 8 pct. **VIVUS INC, $13.28, up 3 pct. Arena said on Thursday that it pulled its application seeking approval for its anti-obesity treatment Belviq in the European Union, lowering competition for rival Vivus, whose obesity pill was recommended for European approval by regulators late last month.

• RESEARCH ALERT-Zions Bancorporation: Guggengeim raises target price Friday, 3 May 2013 | 8:16 AM ET

  May 3-:* Zions Bancorporation: Guggengeim raises target price to $28 from $26; rating neutral. rating buy* Suntrust Banks Inc: Guggengeim raises target price to $33.50 from $32.50; rating neutral* Regions Financial Corp: Guggengeim raises target price to $10 from $9.50; rating buy.

• MARKET PULSE-LinkedIn, Arena Pharma, Radcom, Chemed, Vocera, YRC Worldwide Friday, 3 May 2013 | 12:57 AM ET

  **RADCOM LTD, $4.05, up 53 pct. **LINKEDIN CORP, $181.69, down 10 pct. The U.S. Justice Department is suing the company and its hospice subsidiaries, including the biggest U.S. for-profit hospice chain, alleging false billings for Medicare hospice services.

• REFILE-RESEARCH ALERT-Zions Bancorporation: Guggenheim raises target price Friday, 3 May 2013 | 12:24 AM ET

  *Zions Bancorporation: Guggenheim raises target price to $28 from $26; rating neutral. *Wells Fargo& Co: Guggenheim raises target price to $47 from $46.50; rating buy. *Citigroup Inc: Guggenheim raises price target to $58 from $57; rating buy.

• China Gets Tough on Property Sales Monday, 4 Mar 2013 | 10:08 AM ET

  

  The Shanghai Index fell 3.7 percent as China gets serious about reining in the property sector, ordering a stricter enforcement of sales taxes.